European equities traded in the US as American depositary receipts were trending higher late Thursday morning, rising 0.80% to 1,586.74 on the S&P Europe Select ADR Index.

From continental Europe, the gainers were led by biopharmaceutical companies DBV Technologies (DBVT) and Cellectis (CLLS), which climbed 11% and 8.8%, respectively. They were followed by pharmaceutical company Sanofi (SNY) and telecommunications company Nokia (NOK), which advanced 2.4% and 2.3%, respectively.

The decliners from continental Europe were led by medical device maker EDAP TMS (EDAP) and biotech firm Evaxion (EVAX), which fell 5% and 2.5%, respectively. They were followed by semiconductor company Sequans Communications (SQNS) and biopharmaceutical company Genfit (GNFT), which lost 1.6% and 0.7%, respectively.

From the UK and Ireland, the gainers were led by biopharmaceutical companies Adaptimmune Therapeutics (ADAP) and Biodexa Pharmaceuticals (BDRX), which surged 27% and 6.7%, respectively. They were followed by biopharmaceutical company Bicycle Therapeutics (BCYC) and alcoholic beverage company Diageo (DEO), which was up 5.2% and 3.2%, respectively.

The decliners from the UK and Ireland were led by biotech firm Trinity Biotech (TRIB) and software company Endava (DAVA), which dropped 4.1% and 2%, respectively. They were followed by insurance company Prudential (PUK) and biotech firm Autolus Therapeutics (AUTL), which were down 1% and 0.6%, respectively.